2023
DOI: 10.1002/jcph.2362
|View full text |Cite
|
Sign up to set email alerts
|

Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam

Lisa T. van der Heijden,
Claire A. Ribbers,
Marit A.C. Vermunt
et al.

Abstract: Patients with Prostate Cancer (PCa) have a lower docetaxel exposure for both intravenous (1.8‐fold) and oral administration (2.4‐fold) than patients with other solid cancers, which could influence efficacy and toxicity. An altered metabolism by Cytochrome P450 3A (CYP3A) due to castration status might explain the observed difference in docetaxel pharmacokinetics. In this in vivo phenotyping, pharmacokinetic study CYP3A activity defined by midazolam clearance (Cl) was compared between patients with PCa and male… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 37 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?